

10 – Chronic Hepatitis

Speaker: David Thomas, MD



Chronic Hepatitis


David Thomas, MD
Stanhope Bayne Jones Professor of Medicine
Johns Hopkins University

7/1/2024



Disclosures of Financial Relationships with Relevant Commercial Interests

- Data and Safety Monitoring Board: Merck
- Advisory Board: Merck, Excision Bio



Case: Hepatitis C and a rash



PREVIEW QUESTION

A 44 year old, anti-HCV and HCV RNA positive man feels bad after a recent alcohol binge. He has a chronic rash on arms that is worse and elevated ALT and AST.



O'Connor Mayo Clin Proc 1998

Question: HCV with a rash



PREVIEW QUESTION

The most likely dx is:

- Cirrhosis due to HCV and alcohol
- Necrolytic acral erythema
- Porphyria cutanea tarda
- Essential mixed cryoglobulinemia
- Yersinia infection

Porphyria Cutanea Tarda Associated with Hepatitis C

Tejesh S. Patel, M.D., and Evgeniya Teterina Mohammed, M.D.




June 10, 2021

N Engl J Med 2021; 384:e86

10 – Chronic Hepatitis

Speaker: David Thomas, MD



Question: What is true regarding testing for HCV antibodies?

- A. Testing indicated only for those with risk
- B. New 4th generation antibody/ag test sensitive for acute infection
- C. Indicated for pregnant women
- D. Repeat after cure if new exposures
- E. Often falsely negative in persons with HIV

IDSA/AASLD guidelines

Recommendations for One-Time Hepatitis C Testing	
RECOMMENDED	RATING [ⓐ]
One-time, routine, opt out HCV testing is recommended for all individuals aged 18 years or older.	I, B
One-time HCV testing should be performed for all persons less than 18 years old with activities, exposures, or conditions or circumstances associated with an increased risk of HCV infection (see below).	I, B
Prenatal HCV testing as part of routine prenatal care is recommended with each pregnancy.	I, B
Periodic repeat HCV testing should be offered to all persons with activities, exposures, or conditions or circumstances associated with an increased risk of HCV exposure (see below).	Ila, C
Annual HCV testing is recommended for all persons who inject drugs, for HIV-infected men who have unprotected sex with men, and men who have sex with men taking pre-exposure prophylaxis (PrEP).	Ila, C

RECOMMENDATION The USPSTF recommends screening for HCV infection in adults aged 18 to 79 years. (B recommendation)

JAMA. doi:10.1001/jama.2020.1123
Published online March 2, 2020.

Case: 54 y/o with HCV antibodies and RNA

54 year old man was anti-HCV pos after routine screen by primary. RNA also pos; moderate ETOH; otherwise well. CMP and CBC were normal.

Question: 54 y/o with HCV antibodies and RNA

Which of is most necessary before treatment:

- A. HCV genotype
- B. HCV 1a resistance test
- C. Elastography
- D. HBsAg
- E. Repeat in 6 month to be sure chronic

10 – Chronic Hepatitis

Speaker: David Thomas, MD

FDA Drug Safety Communications

FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C

All are tested for HBV

- HBsAg pos: treat per HBV guidelines
- Anti-HBc pos: monitor

Bersoff-Macha Ann Intern Med 2017; Thio and Balagopal CID 2015

Staging is needed to assess for cirrhosis (but not urgent)

Accepted staging methods	Not for routine staging
1. Liver biopsy	1. Viral load
2. Blood markers	2. HCV genotype
3. Elastography	3. Ultrasound
4. Combinations of 1-3	4. CT scan or MRI

Hcvguidelines.org

HCV NS5 RAS testing is uncommonly recommended

Regimen-Specific Recommendations for Use of RAS Testing in Clinical Practice	RECOMMENDED	RATING Ⓢ
Elbasvir/grazoprevir NS5A RAS testing is recommended for genotype 1a-infected, treatment-naïve or re-treatment patients being considered for elbasvir/grazoprevir. If present, a different regimen should be considered.		I, A
Ledipasvir/sofosbuvir NS5A RAS testing can be considered for genotype 1a-infected, treatment-experienced patients with and without cirrhosis being considered for ledipasvir/sofosbuvir. If clinically important* resistance is present, a different recommended therapy should be used.		I, A
Sofosbuvir/velpatasvir NS5A RAS testing is recommended for genotype 3-infected, treatment-naïve patients with cirrhosis and treatment-experienced patients (without cirrhosis) being considered for 12 weeks of sofosbuvir/velpatasvir. If Y93H is present, weight-based dosing should be added or another recommended regimen should be used.		I, A

* Clinically important = ≥100-fold shift in the in vitro EC₅₀ to ledipasvir



NB: no PI resistance testing
Clinically sig is >100-fold in vitro

Wyles, HCVguidelines.org

Case con't: 54 year old with HCV


Elastography (17.3 kPa) and Fib-4 (5.5) consistent with cirrhosis. Genotype 1a; HBsAg neg; Ultrasound and UGI are ok. Which can you NOT say is true of treatment?

- reduces risk of reinfection
- reduces risk of death
- reduces risk of HCC
- reduces risk of liver failure



10 – Chronic Hepatitis

Speaker: David Thomas, MD



54 year old with HCV

Which is true of initial HCV treatment?

- Avoid sofosbuvir if renal insufficiency
- Avoid glecaprevir (PI) if on atorvastatin
- Avoid sofosbuvir/ledipasvir if genotype 1
- Prolong treatment if person also has HIV

AASLD | HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C | IDSA | Infectious Diseases Society of America

Test, Evaluate, Monitor | Treatment-Naive | Treatment-Experienced | Unique & Key Populations

Recommended regimens listed by evidence level and alphabetically for:

Treatment-Naive Genotype 1a Patients With Compensated Cirrhosis^a

RECOMMENDED	DURATION	RATING
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg)	12 weeks	I, A
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)	12 weeks	I, A
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) ^b	8 weeks	I, B

^a For decompensated cirrhosis, please refer to the appropriate section.
^b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. For patients with HIV/HCV coinfection, a treatment duration of 12 weeks is recommended.

HCV-HIV ART drug interactions

	Ledipasvir/Sofosbuvir (LDV/SOF)	Sofosbuvir/Velpatasvir (SOF/VEL)	Ebavir/Glecaprevir (ELB/GRZ)	Glecaprevir/Pibrentasvir (GLE/PIB)	Sofosbuvir/Velpatasvir (SOF/VEL/VOX)
Protease Inhibitors					
Bosentan	A	A			
Bosentan	A	A			
Bosentan	ND, A	A			ND
Doravirine		ND		ND	ND
Efavirenz		ND		ND	ND
Rilpivirine		ND		ND	ND
NRTIs					
Etravirine	ND	ND	ND	ND	ND
Solunavir		ND	ND	ND	ND
Integrase Inhibitors					
Cabotegravir	ND	ND	ND	ND	ND
Cobicistat-boosted elvitegravir	C	C			C
Dolutegravir					ND
Raltegravir					ND
Entry Inhibitors					
Fostemsavir	ND	ND	ND	ND	ND
Balicizumab-uyk	ND	ND	ND	ND	ND
Marsaxirov	ND	ND	ND	ND	ND
Abacavir	ND	ND	ND	ND	ND
NRTIs					
Emtricitabine					ND
Lamivudine		ND	ND		ND
Tenofovir disoproxil fumarate	B, C	B, C			C
Tenofovir alafenamide	D	D	ND		D

www.hcvguidelines.com

Slide 22 of 44

- ### HCV treatment summary
- Test and treat (and stage)
 - Two pangenotypic regimens: SOF/VEL and G/P
 - Watch for HBV relapse at week 8 if HBsAg pos
 - No change for HIV (avoid drug interactions), renal insufficiency, acute infection
 - Compensated cirrhosis same for G/P and SOF-based except GT3 with resistance

- ### Hepatitis B: 2023 Testing Recs for USA
- Universal hepatitis B virus (HBV) screening
- HBV screening at least once during a lifetime for adults aged ≥18 years (new recommendation)
 - During screening, test for hepatitis B surface antigen (HBsAg), antibody to HBsAg, and total antibody to HBcAg (total anti-HBc) (new recommendation)
- Screening pregnant persons
- HBV screening for all pregnant persons during each pregnancy, preferably in the first trimester, regardless of vaccination status or history of testing^a
 - Pregnant persons with a history of appropriately timed triple panel screening and without subsequent risk for exposure to HBV (i.e., no new HBV exposures since triple panel screening) only need HBsAg screening
- Risk-based testing
- Testing for all persons with a history of increased risk for HBV infection, regardless of age, if they might have been susceptible during the period of increased risk^b
 - Periodic testing for susceptible persons, regardless of age, with ongoing risk for exposures, while risk for exposures persists^b
- MMWR March 10, 2023

10 – Chronic Hepatitis

Speaker: David Thomas, MD

After HBV testing, which requires treatment

- 41 yr male in China HBsAg pos, HBeAg neg, anti-HBe pos, ALT 78 IU/ml, AST 86 IU/ml, HBV DNA 5,600
- 51 yr male HBsAg neg, anti-HBc pos, HBeAg neg, anti-HBe pos, ALT 48 IU/ml, AST 36 IU/ml, HBV DNA neg
- 21 yr woman born in Viet Nam HBsAg pos, HBeAg pos, anti-HBe neg, ALT 18 IU/ml, AST 16 IU/ml, HBV DNA 8.2 mil
- 62 yr woman about to start hydroxychloroquine for SLE anti-HBc pos, HBsAg neg, HBeAg neg, anti-HBe pos, DNA neg, ALT 34 IU/ml, AST 28 IU/ml
- 19 yr man about to start college anti-HBs pos, HBsAg neg, HBeAg neg, DNA neg, ALT 18 IU/ml, AST 12 IU/ml

After HBV testing, which requires treatment


Age (yrs)	DNA (IU/ml)	ALT (IU/ml)	Issue/interpretation
41	5600	78	Chronic HBV with replication and inflammation
51	Neg	48	Isolated core/possible occult HB. Probable MASLD
21	8,200,000	18	High replication without inflammation (immunotolerant)
62	Neg	34	Isolated core/possible occult. Mild immunosuppression
19	Neg	18	Vaccinated

Treatment of chronic hepatitis B (HBsAg pos)

- Disease (ALT and/or biopsy and/or elastography) + Replication (HBV DNA > 2,000 IU/ml)
- Cirrhosis- treat all
- HIV – treat all
- Pregnancy- treat if HBV DNA > 200,000 IU/ml

Test pregnant women for HBsAg and, if pos, for HBV DNA* and treat if > 200,000 IU/ml

Rec for all pregnant women to have quantitative HBV DNA TEST



*test in 3rd trimester

Terrault Hepatology 2015; Pan NEJM 2016

Evaluation of persons with CHB

- HIV, HBV DNA, anti-HDV, HBeAg
- Genotype if IFN considered; q HBsAg if 'covered'
- Stage (liver enzymes and/or elastography or biopsy)
- Renal status
- US to r/o HCC
 - Cirrhosis: all
 - Asian: male 40; female 50
 - African: 25-30

Four preferred treatments for chronic hepatitis B

HBsAg Positive	Peg-IFN*	Entecavir [†]	Tenofovir Disoproxil Fumarate [†]	Tenofovir Alafenamide [‡]
% HBV DNA suppression (cutoff to define HBV-DNA suppression) [§]	30-42 (<2,000-40,000 IU/mL)	61 (<50-60 IU/mL)	76 (<60 IU/mL)	73 (<29 IU/mL)
% HBsAg loss	32-36	22-25	—	22
% HBsAg seroconversion	29-36	21-22	21	18
% Normalization ALT [¶]	34-52	68-81	68	—
% HBsAg loss	2-7	4-5	8	1
11 (at 3 years posttreatment)				
HBsAg Negative	Peg-IFN	Entecavir	Tenofovir Disoproxil Fumarate [†]	Tenofovir Alafenamide [‡]
% HBV DNA suppression (cutoff to define HBV-DNA suppression) [§]	43 (<4,000 IU/mL)	90-91 (<50-60 IU/mL)	93 (<60 IU/mL)	90 (<29 IU/mL)
% Normalization ALT [¶]	59	78-88	76	81
% HBsAg loss	4	0-1	0	<1
6 (at 3 years posttreatment)				

TAF 25 mg with or without FTC

AASLD guidelines, Terrault Hepatology 2018

10 – Chronic Hepatitis

Speaker: David Thomas, MD

Treatment of HBV changes with renal insufficiency

- GFR 30-60 mL/min/1.73 m²: TAF 25 mg preferred
- GFR <30-10: TAF 25mg OR entecavir 0.5 mg q 3d
- GFR <10 no dialysis: entecavir 0.5 mg
- Dialysis: TDF 300mg/wk PD or entecavir 0.5mg/wk or TAF 25mg PD

HIV/HBV coinfect need treatment for both

- All are treated and tested for both
- HBV-active ART
- Entecavir less effective if LAM exposure
- Watch switch from TAF- or TDF-containing regimen

It is hard to stop HBV treatment

- If HBeAg conversion noted and no cirrhosis *consider* stopping after 6 months
- HBeAg neg when treatment started and all with cirrhosis stay on indefinitely
- (Newer practice is to use quantitative HBsAg and stop only when low (eg <100))



PREVIEW QUESTION

Hepatitis serology in the oncology suite

You are called about 62 year old Vietnamese scientist who is in oncology suite where he is about to get R-CHOP for Non Hodgkins lymphoma.

Baseline labs: normal AST, ALT, and TBil. Total HAV detectable; anti-HBc pos; HBsAg neg; anti-HCV neg.



PREVIEW QUESTION

What do you recommend?

- A. Hold rituximab
- B. Hold prednisone
- C. Entecavir 0.5 mg
- D. HCV PCR

Rituximab, high-dose prednisone, and BM transplant high risk for HBV reactivation

- If HBsAg pos, prophylaxis *always* recommended
- If anti-HBc pos but HBsAg neg, prophylaxis still recommended with high-risk exposures (anti-CD20, high dose Pred, BM tx)
- Use TAF or ETV for 6-12 mo after dc immunosuppression (12 for anti-CD20)

AASLD Terrault Hepatology 2018

10 – Chronic Hepatitis

Speaker: David Thomas, MD

Chronic hepatitis in a transplant recipient

51 y/o HTN, and ankylosing spondylitis s/p renal transplant presents with elevated liver enzymes. Pred 20/d; MMF 1g bid; etanercept 25mg twice/wk; tacro 4mg bid. Hunts wild boar in Texas

HBsAg neg, anti-HBs pos, anti-HBc neg; anti-HCV neg; HCV RNA neg; CMV IgG neg; EBV neg; VZV neg. ALT 132 IU/ml, AST 65 IU/ml; INR 1. ALT and AST remained elevated; HBV, HCV, HAV, CMV, EBV serologies remain neg.


Barrague Medicine 2017

Which test is most likely abnormal

1. HEV PCR
2. HCV IgM
3. Tacrolimus level
4. Adenovirus PCR
5. Delta RNA PCR

Chronic HEV in transplant recipient

- Europe (boar)
- Can cause cirrhosis
- Tacrolimus associated
- Ribavirin may be effective



Barrague Medicine 2017

Chronic Hepatitis for the Boards Summary

- HCV-associated conditions: PCT or cryoglobulinemia
- HCV: HBV relapse or drug interaction
- HBV: relapse post rituximab
- HEV: chronic in transplant patient
- Guess b and good luck

Thanks and good luck on the test!

Questions:

Dave Thomas

-dthomas@jhmi.edu